Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNFT GENFIT	$4.32 +4.8%	$3.90	$2.55 ▼ $6.42	$219.08M	1.14	3,812 shs	1,582 shs
IPHA Innate Pharma	$2.25 +0.9%	$1.97	$1.29 ▼ $3.51	$207.41M	0.22	13,002 shs	4,578 shs
OGI Organigram Global	$1.60 +1.9%	$1.44	$0.85 ▼ $2.05	$214.48M	1.45	938,733 shs	894,643 shs
PRLD Prelude Therapeutics	$1.24 +12.7%	$0.87	$0.61 ▼ $5.95	$70.18M	1.22	171,541 shs	486,756 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNFT GENFIT	0.00%	+8.17%	+6.31%	+2.03%	-1.95%
IPHA Innate Pharma	0.00%	+5.39%	+10.59%	+4.41%	-0.44%
OGI Organigram Global	0.00%	+11.89%	+5.96%	+16.79%	-20.79%
PRLD Prelude Therapeutics	0.00%	+42.53%	+35.96%	+39.92%	-76.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNFT GENFIT	2.1575 of 5 stars	3.5	3.0	3.3	0.0	0.0
IPHA Innate Pharma	1.7039 of 5 stars	3.7	2.0	0.6	1.7	0.0
OGI Organigram Global	0.3841 of 5 stars	0.0	2.0	1.5	0.0	1.3
PRLD Prelude Therapeutics	2.8068 of 5 stars	3.5	3.0	0.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNFT GENFIT	3.00	Buy	$9.00	108.53% Upside
IPHA Innate Pharma	3.33	Buy	$11.00	388.89% Upside
OGI Organigram Global	0.00	N/A	N/A	N/A
PRLD Prelude Therapeutics	3.00	Buy	$4.00	222.58% Upside

Current Analyst Ratings Breakdown

Latest PRLD, OGI, IPHA, and GNFT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	GNFT GENFIT	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/18/2025	PRLD Prelude Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$4.00 ➝ $3.00
7/28/2025	IPHA Innate Pharma	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNFT GENFIT	$76.77M	2.81	$0.07 per share	62.64	$1.50 per share	2.88
IPHA Innate Pharma	$21.77M	9.53	N/A	N/A	$0.11 per share	20.45
OGI Organigram Global	$117.47M	1.83	N/A	N/A	$2.08 per share	0.77
PRLD Prelude Therapeutics	$7M	10.03	N/A	N/A	$1.34 per share	0.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNFT GENFIT	$1.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
OGI Organigram Global	-$33.39M	$0.05	32.01	N/A	N/A	2.86%	-8.19%	-5.79%	N/A
PRLD Prelude Therapeutics	-$127.17M	-$1.64	N/A	N/A	N/A	N/A	-106.50%	-79.07%	11/5/2025 (Estimated)

Latest PRLD, OGI, IPHA, and GNFT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	PRLD Prelude Therapeutics	-$0.45	-$0.41	+$0.04	-$0.41	N/A	N/A
8/13/2025	Q3 2025	OGI Organigram Global	-$0.01	-$0.03	-$0.02	-$0.03	$68.04 million	$50.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNFT GENFIT	N/A	N/A	N/A	N/A	N/A
IPHA Innate Pharma	N/A	N/A	N/A	N/A	N/A
OGI Organigram Global	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNFT GENFIT	0.08	1.23	1.23
IPHA Innate Pharma	2.52	2.60	2.60
OGI Organigram Global	N/A	2.59	1.42
PRLD Prelude Therapeutics	N/A	3.68	5.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNFT GENFIT	2.24%
IPHA Innate Pharma	0.16%
OGI Organigram Global	34.63%
PRLD Prelude Therapeutics	79.72%

Insider Ownership

Company	Insider Ownership
GNFT GENFIT	4.20%
IPHA Innate Pharma	31.89%
OGI Organigram Global	0.09%
PRLD Prelude Therapeutics	63.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNFT GENFIT	120	50.00 million	47.90 million	Not Optionable
IPHA Innate Pharma	220	92.18 million	62.79 million	Not Optionable
OGI Organigram Global	860	134.05 million	133.93 million	Optionable
PRLD Prelude Therapeutics	120	56.60 million	20.43 million	Optionable

PRLD, OGI, IPHA, and GNFT Headlines

Recent News About These Companies

Prelude Therapeutics price target lowered to $3 from $4 at Citizens JMP

August 19, 2025 | msn.com

JMP Securities Cuts Prelude Therapeutics (NASDAQ:PRLD) Price Target to $3.00

August 19, 2025 | americanbankingnews.com

Prelude Cuts Q2 Losses and Costs 13%

August 14, 2025 | aol.comA

Prelude Therapeutics Pauses Intravenous SMARCA2 Degrader Development

August 14, 2025 | msn.com

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025 | globenewswire.com

Can Prelude Therapeutics (NASDAQ:PRLD) Afford To Invest In Growth?

August 11, 2025 | finance.yahoo.com

Prelude Therapeutics (NASDAQ:PRLD) Trading 2% Higher - Time to Buy?

July 26, 2025 | marketbeat.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics Incorporated (PRLD) - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025

June 3, 2025 | msn.com

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025 | globenewswire.com

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges

May 28, 2025 | investing.com

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

May 15, 2025 | fiercebiotech.comF

Prelude Therapeutics Reports Q1 2025 Financial Results and Progress on Clinical Programs

May 10, 2025 | msn.com

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025 | globenewswire.com

Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025

May 4, 2025 | msn.com

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025 | globenewswire.com

Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies

April 30, 2025 | msn.com

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025 | globenewswire.com

Prelude Therapeutics (PRLD) Upgraded to Buy: Here's What You Should Know

April 10, 2025 | zacks.com

Prelude Therapeutics Founder Acquires 28% More Stock

March 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PRLD, OGI, IPHA, and GNFT Company Descriptions

GENFIT NASDAQ:GNFT

$4.32 +0.20 (+4.76%)

As of 08/22/2025 03:56 PM Eastern

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Innate Pharma NASDAQ:IPHA

$2.24 +0.02 (+0.67%)

As of 08/22/2025 03:59 PM Eastern

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Organigram Global NASDAQ:OGI

$1.60 +0.03 (+1.91%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.59 -0.01 (-0.63%)

As of 08/22/2025 07:59 PM Eastern

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.

Prelude Therapeutics NASDAQ:PRLD

$1.24 +0.14 (+12.73%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.25 +0.01 (+1.21%)

As of 08/22/2025 07:59 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time